Cargando…
The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis
Objective: To determine the association between baseline ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) antigen level and 90-days clinical outcome in patients with acute ischemic stroke (AIS) receiving recombinant tissue plasminogen activator (rt-PA) thr...
Autores principales: | Su, Ya, Chen, Xin, Ye, Xiaofei, Sun, Haiyan, Wu, Fei, Dong, Qiang, Cheng, Xin, Wu, Danhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412597/ https://www.ncbi.nlm.nih.gov/pubmed/32849241 http://dx.doi.org/10.3389/fneur.2020.00799 |
Ejemplares similares
-
ADAMTS13: An Emerging Target in Stroke Therapy
por: Chen, Xin, et al.
Publicado: (2019) -
Characteristics and Outcomes of Intravenous Thrombolysis in Mild Ischemic Stroke Patients
por: Tang, Huan, et al.
Publicado: (2021) -
Impact of homocysteine levels on clinical outcome in patients with acute ischemic stroke receiving intravenous thrombolysis therapy
por: Li, Lei, et al.
Publicado: (2020) -
Intravenous Thrombolysis in Ischemic Stroke Patients With Active Cancer
por: Selvik, Henriette Aurora, et al.
Publicado: (2018) -
Stress Hyperglycemia Does Not Affect Clinical Outcome of Diabetic Patients Receiving Intravenous Thrombolysis for Acute Ischemic Stroke
por: Merlino, Giovanni, et al.
Publicado: (2022)